Dynamic Anthropometrics in Pancreatic Cancer: Associations Between Body Composition Changes During Neoadjuvant Therapy and Survival Outcomes After Resection

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2024 Aug 9

PMID 39120842

Authors

Elliott J Yee

Robert J Torphy

Emily K Myers

Cheryl Meguid

Oskar Franklin

Toshitaka Sugawara

Salvador Rodriguez Franco

Toshimasa J Clark

Benedetto Mungo

Steven A Ahrendt

Richard D Schulick

Marco Del Chiaro

Martin M McCarter

Affiliations

Soon will be listed here.

Abstract

Background: Assessment of individual tumor biology and response to systemic therapy in pancreatic ductal adenocarcinoma (PDAC) remains a clinical challenge. The significance of anthropometric (body composition) changes during chemotherapy as a surrogate for tumor biology in the setting of localized PDAC is unknown.

Methods: A retrospective, single-institution analysis of patients with PDAC who received neoadjuvant therapy (NAT) and pancreatectomy from 2017 to 2021 was performed. Radiologic anthropometric analysis used artificial intelligence-driven software to segment and compute total and sub-compartment muscle area, adipose tissue area, and attenuation values at the level of the L3 vertebra. Kaplan-Meier survival estimates, log-rank tests, and multivariable Cox regression models were used in survival analyses.

Results: The inclusion criteria were met by 138 patients. Although decreases in muscle and adipose tissue areas during NAT were predominant, a subset of patients experienced an increase in these compartments. Increases in muscle greater than 5% (hazard ratio [HR], 0.352; 95% confidence interval [CI] 0.135-0.918; p = 0.033) and increases in adipose tissue greater than 15% (HR, 0.375; 95% CI 0.144-0.978; p = 0.045), were significantly associated with improved survival, whereas loss of visceral fat greater than 15% was detrimental (HR 1.853; CI 1.099-3.124; p = 0.021). No significant associations with single time-point anthropometrics were observed. Gains in total muscle and adipose mass were associated with improved pathologic response to systemic therapy and less advanced pathologic tumor stage.

Conclusions: Dynamic anthropometric analysis during NAT for PDAC is a stronger prognostic indicator than measurements taken at a single point in time. Repeated anthropometric analysis during preoperative chemotherapy may serve as a biomarker for individual tumor biology and response to therapy.

Citing Articles

ASO Author Reflections: Clinical Relevance of Mitochondrial Status in Patients with Esophageal Squamous Cell Carcinoma.

Sugawara K, Sakashita S, Motoi N Ann Surg Oncol. 2024; 32(3):1987-1988.

PMID: 39623186 DOI: 10.1245/s10434-024-16573-2.

References

Boone B, Steve J, Zenati M, Hogg M, Singhi A, Bartlett D . Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol. 2014; 21(13):4351-8. DOI: 10.1245/s10434-014-3842-z. View

Argiles J, Lopez-Soriano F, Stemmler B, Busquets S . Cancer-associated cachexia - understanding the tumour macroenvironment and microenvironment to improve management. Nat Rev Clin Oncol. 2023; 20(4):250-264. DOI: 10.1038/s41571-023-00734-5. View

Peixoto da Silva S, Santos J, Costa E Silva M, Gil da Costa R, Medeiros R . Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia. J Cachexia Sarcopenia Muscle. 2020; 11(3):619-635. PMC: 7296264. DOI: 10.1002/jcsm.12528. View

Kordes M, Larsson L, Engstrand L, Lohr J . Pancreatic cancer cachexia: three dimensions of a complex syndrome. Br J Cancer. 2021; 124(10):1623-1636. PMC: 8110983. DOI: 10.1038/s41416-021-01301-4. View

Fang P, Zhou J, Xiao X, Yang Y, Luan S, Liang Z . The prognostic value of sarcopenia in oesophageal cancer: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022; 14(1):3-16. PMC: 9891912. DOI: 10.1002/jcsm.13126. View

Caan B, Cespedes Feliciano E, Prado C, Alexeeff S, Kroenke C, Bradshaw P . Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer. JAMA Oncol. 2018; 4(6):798-804. PMC: 6584322. DOI: 10.1001/jamaoncol.2018.0137. View

Vergara-Fernandez O, Trejo-Avila M, Salgado-Nesme N . Sarcopenia in patients with colorectal cancer: A comprehensive review. World J Clin Cases. 2020; 8(7):1188-1202. PMC: 7176615. DOI: 10.12998/wjcc.v8.i7.1188. View

Chianca V, Albano D, Messina C, Gitto S, Ruffo G, Guarino S . Sarcopenia: imaging assessment and clinical application. Abdom Radiol (NY). 2021; 47(9):3205-3216. PMC: 8536908. DOI: 10.1007/s00261-021-03294-3. View

Wang J, Williams M . Exploring definitions of radiological sarcopenia in cancer: a protocol for a scoping review. BMJ Open. 2021; 11(7):e053076. PMC: 8256756. DOI: 10.1136/bmjopen-2021-053076. View

10.

Onesti J, Wright G, Kenning S, Tierney M, Davis A, Doherty M . Sarcopenia and survival in patients undergoing pancreatic resection. Pancreatology. 2016; 16(2):284-9. DOI: 10.1016/j.pan.2016.01.009. View

11.

Amini N, Spolverato G, Gupta R, Margonis G, Kim Y, Wagner D . Impact Total Psoas Volume on Short- and Long-Term Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess Sarcopenia. J Gastrointest Surg. 2015; 19(9):1593-602. PMC: 4844366. DOI: 10.1007/s11605-015-2835-y. View

12.

Joglekar S, Asghar A, Mott S, Johnson B, Button A, Clark E . Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma. J Surg Oncol. 2015; 111(6):771-5. PMC: 4406850. DOI: 10.1002/jso.23862. View

13.

Katz M, Shi Q, Meyers J, Herman J, Chuong M, Wolpin B . Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022; 8(9):1263-1270. PMC: 9284408. DOI: 10.1001/jamaoncol.2022.2319. View

14.

Cooper A, Slack R, Fogelman D, Holmes H, Petzel M, Parker N . Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. Ann Surg Oncol. 2014; 22(7):2416-23. PMC: 11831732. DOI: 10.1245/s10434-014-4285-2. View

15.

Sandini M, Patino M, Ferrone C, Alvarez-Perez C, Honselmann K, Paiella S . Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer. JAMA Surg. 2018; 153(9):809-815. PMC: 6583880. DOI: 10.1001/jamasurg.2018.0979. View

16.

Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin M, McCargar L . Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013; 31(12):1539-47. DOI: 10.1200/JCO.2012.45.2722. View

17.

Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M . The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017; 161(3):584-591. DOI: 10.1016/j.surg.2016.11.014. View

18.

Clavien P, Barkun J, De Oliveira M, Vauthey J, Dindo D, Schulick R . The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009; 250(2):187-96. DOI: 10.1097/SLA.0b013e3181b13ca2. View

19.

Jang M, Park C, Hong S, Li H, Rhee E, Doorenbos A . Skeletal Muscle Mass Change During Chemotherapy: A Systematic Review and Meta-analysis. Anticancer Res. 2020; 40(5):2409-2418. DOI: 10.21873/anticanres.14210. View

20.

Au P, Li H, Lee G, Hoi-Yee Li G, Chan M, Cheung B . Sarcopenia and mortality in cancer: A meta-analysis. Osteoporos Sarcopenia. 2021; 7(Suppl 1):S28-S33. PMC: 8088991. DOI: 10.1016/j.afos.2021.03.002. View